aily preserves efficacy EPO906 Epothilone B and improves tolerability in imatinib-resistant and -intolerant chronicphase chronic myeloid leukemia. J Clin Oncol. 2008, 26:3204�?2. 52. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010, 116:377�?6. 53. Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009, 27:3472�?. 54. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005, 7:129�?1.
55. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 : a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006, 94:1765�?. 56. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006, 354:2542�?1. 57. le Coutre P, Ottmann OG, Giles F, fgfr pathway et al. Nilotinib , a highly selective BCRABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008, 111:1834�?. 58. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib , a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Blood. 2007, 110:3540�?. Woessner et al. Page 12 Cancer J. Author manuscript, available in PMC 2012 May 1. NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript 59. Koren-Michowitz M, le Coutre P, Duyster J, et al. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant. Cancer. 2010, 116:4564�?2. 60. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib therapy. Leukemia. 2002, 16:2190�?. 61. Gromicho M, Dinis J, Magalhaes M, et al. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1. Leuk Lymphoma. 2011 62.
Bradeen HA, Eide CA, O,Hare T, et al. Comparison of imatinib mesylate, dasatinib , and nilotinib in an N-ethyl-N-nitrosourea -based mutagenesis screen: high efficacy of drug combinations. Blood. 2006, 108:2332�?. 63. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib. Blood. 2006, 108:1328�?3. 64. O,Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007, 110:2242�?. 65. Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
J Clin Oncol. 2010, 28:e169�?1. author reply e72. 66. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008, 112:3330�?. 67. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid l